The monoclonal antibody nemolizumab has shown sustained efficacy in treating moderate-to-severe atopic dermatitis (AD), with significant improvements in skin clarity and pruritus observed over a period of 104 weeks, according to recent findings from the ARCADIA Long-Term Extension (LTE) study.
Study Design and Participants
The ARCADIA LTE study enrolled 1,901 patients with moderate-to-severe AD. Participants received nemolizumab every four weeks in combination with topical treatments. The study included both nemolizumab-naïve patients and those who had previously received the drug.
Key Findings
Over 55% of patients achieved clear or almost clear skin, with a majority reaching the EASI-75 endpoint, indicating a 75% reduction in Eczema Area and Severity Index (EASI) scores. These results highlight the drug’s effectiveness in managing severe symptoms of atopic dermatitis.
Quality of Life and Safety Profile
Both nemolizumab-naïve and previously treated patients experienced clinically meaningful improvements in quality of life. The study also reported that treatment-emergent adverse events were minor, suggesting that nemolizumab is well-tolerated over the long term.
Implications for Treatment
The sustained efficacy and favorable safety profile of nemolizumab demonstrated in the ARCADIA LTE study suggest that it could be a valuable option for patients with moderate-to-severe atopic dermatitis. These findings add to the growing body of evidence supporting the use of targeted biologics in managing chronic inflammatory skin conditions.
Related topics:
